Staff
Writer, MedPage Today
Nov. 11, 2015
 |
| Dr. Philip Kennedy |
Neuroscientist Phil Kennedy takes
self-experimentation to the extreme by flying to Belize to have
electrodes implanted into his brain for data collection. (MIT Technology
Review)
An FDA advisory committee backed Merck's
muscle-relaxant reversal drug sugammadex, but will the agency
finally approve a drug it snubbed several times over? (Reuters)
The CEO of Insys
Therapeutics stepped down after a report that the company pushed its
painkiller Subsys, a sublingual spray formulation of fentanyl, far
beyond its labeled indication. (CNBC)
A University of Illinois at
Chicago investigation found evidence of
misconduct in research papers by a psychiatrist who has received
millions of dollars in federal funding. One paper has been retracted and two
more are likely to be pulled. (Retraction Watch)
The CDC says there's no geographic
link between Lyme disease and deaths from other neurodegenerative disorders
like Alzheimer's, ALS, multiple sclerosis, or Parkinson's.
The brain's GPS cells may also
help us navigate our
memories through time, according to a mouse study. (Neuron)
Medical Marketing & Media takes a look at the therapeutic
space in neurology.
MRI biomarkers
may help track progression in muscle-wasting disorders. (Lancet Neurology)
Three neuroscientists have taken
home Breakthrough Prizes.
The lucrative prizes were set up by top Silicon Valley entrepreneurs, including
Facebook's Mark Zuckerberg and Google co-founder Sergey Brin, just 3 years ago.
(STAT News)
http://www.medpagetoday.com/Neurology/GeneralNeurology/54611?isalert=1&uun=g972365d4649R8295642u&xid=NL_breakingnews_2015-11-10
No comments:
Post a Comment